X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (428) 428
index medicus (345) 345
diabetes mellitus, type 2 - drug therapy (293) 293
type 2 diabetes (278) 278
glucagon-like peptide-1 (275) 275
endocrinology & metabolism (215) 215
incretin (209) 209
male (193) 193
diabetes (186) 186
animals (184) 184
hypoglycemic agents - therapeutic use (178) 178
pharmacology & pharmacy (161) 161
glucose (144) 144
glp-1 (140) 140
female (135) 135
insulin (125) 125
glycemic control (123) 123
double-blind (121) 121
liraglutide (117) 117
pharmacokinetics (116) 116
blood glucose - drug effects (110) 110
hypoglycemic agents - adverse effects (110) 110
middle aged (110) 110
glucagon (108) 108
hypoglycemic agents - pharmacology (108) 108
blood glucose - metabolism (107) 107
adult (104) 104
exenatide (98) 98
diabetes mellitus, type 2 - blood (95) 95
hypoglycemic agents - administration & dosage (94) 94
hypoglycemic agents - pharmacokinetics (90) 90
dipeptidyl-peptidase iv inhibitors - therapeutic use (89) 89
glucagon-like peptide 1 - analogs & derivatives (89) 89
incretins (89) 89
treatment outcome (88) 88
review (87) 87
dipeptidyl peptidase-4 inhibitor (85) 85
sitagliptin (83) 83
beta-cell function (82) 82
peptides (79) 79
glucagon-like peptide 1 (77) 77
hypoglycemic agents (76) 76
safety (76) 76
type-2 diabetes-mellitus (76) 76
insulin - blood (74) 74
drug therapy (72) 72
type 2 diabetes mellitus (71) 71
insulin - metabolism (70) 70
metformin (70) 70
aged (66) 66
diabetes mellitus (65) 65
incretin-based therapies (62) 62
diabetes therapy (61) 61
drug therapy, combination (60) 60
incretins - therapeutic use (60) 60
glucagon-like peptide 1 - therapeutic use (59) 59
care and treatment (58) 58
dextrose (57) 57
diabetes mellitus, type 2 - metabolism (57) 57
efficacy (57) 57
endocrine system (57) 57
research (57) 57
sitagliptin phosphate (57) 57
vildagliptin (57) 57
dipeptidyl-peptidase iv inhibitors - adverse effects (56) 56
dose-response relationship, drug (56) 56
health aspects (56) 56
secretion (56) 56
incretin hormones (55) 55
digestive, oral, and skin physiology (54) 54
gastric-inhibitory polypeptide (54) 54
internal medicine (54) 54
obesity (53) 53
analysis (52) 52
glucagon-like peptide 1 - blood (52) 52
insulin secretion (52) 52
mice (52) 52
rats (52) 52
double-blind method (51) 51
peptides - therapeutic use (48) 48
pharmacodynamics (48) 48
diabetes mellitus, type 2 - physiopathology (47) 47
dipeptidyl-peptidase iv inhibitors - pharmacology (47) 47
dpp-4 inhibitor (47) 47
glucagon-like peptide 1 - metabolism (47) 47
glucagon-like peptide-1 receptor (47) 47
glycated hemoglobin a - metabolism (47) 47
open-label (47) 47
peptides - pharmacology (47) 47
glucagon-like peptide 1 - pharmacology (46) 46
physiological aspects (46) 46
hormones, hormone substitutes, and hormone antagonists (45) 45
improves glycemic control (45) 45
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (42) 42
administration, oral (41) 41
incretins - metabolism (41) 41
insulin-secretion (41) 41
adamantane - analogs & derivatives (40) 40
dependent insulinotropic polypeptide (40) 40
dosage and administration (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (618) 618
Korean (4) 4
German (3) 3
Spanish (3) 3
French (2) 2
Chinese (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Kidney International, ISSN 0085-2538, 02/2015, Volume 87, Issue 2, pp. 308 - 322
This review mainly focuses on metformin, and considers oral antidiabetic therapy in kidney transplant patients and the potential benefits and risks of... 
Type 2 diabetes | lactic acidosis | pharmacokinetics | metformin | chronic kidney disease | antidiabetic agents | ORGANIC CATION TRANSPORTER-1 | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | OXYGEN-CONSUMPTION | INDUCED HYPOGLYCEMIA | CLINICAL PHARMACOKINETICS | IN-VITRO DEGRADATION | UROLOGY & NEPHROLOGY | MITOCHONDRIAL DYSFUNCTION | LACTIC-ACIDOSIS | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Diabetic Nephropathies - drug therapy | Glycoside Hydrolase Inhibitors - therapeutic use | Incretins - pharmacokinetics | Diabetes Mellitus, Type 2 - metabolism | Metformin - adverse effects | Thiazolidinediones - pharmacokinetics | Thiazolidinediones - therapeutic use | Glycoside Hydrolase Inhibitors - pharmacokinetics | Acidosis, Lactic - etiology | Renal Insufficiency - drug therapy | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Metformin - pharmacokinetics | Diabetic Nephropathies - metabolism | Sulfonylurea Compounds - therapeutic use | Renal Insufficiency - metabolism | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Acidosis, Lactic - metabolism | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - pharmacokinetics | Insulin - therapeutic use | Kidney Transplantation - adverse effects
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2006, Volume 46, Issue 8, pp. 876 - 886
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 352 - 361
Aim To evaluate the efficacy, pharmacokinetic (PK) profile and tolerability of subcutaneous (s.c.). exendin 9‐39 (Ex‐9) injection in patients with... 
pharmacokinetics | incretins | bariatric surgery | GLP‐1 | hypoglycaemia | pharmacodynamics | GLP-1 | MIXED-MEAL | STIMULATION | INSULIN-SECRETION | HUMANS | SYMPTOMS | BETA-CELL FUNCTION | GASTRIC BYPASS-SURGERY | GLUCAGON-LIKE PEPTIDE-1 | GLUCOSE | ENDOCRINOLOGY & METABOLISM | Glucagon-Like Peptide-1 Receptor - antagonists & inhibitors | Single-Blind Method | Postoperative Complications - etiology | Area Under Curve | Humans | Middle Aged | Postoperative Complications - blood | Postoperative Complications - metabolism | Postoperative Complications - prevention & control | Half-Life | Insulin - blood | Glucose Tolerance Test - adverse effects | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Glucagon-Like Peptide-1 Receptor - metabolism | Hyperinsulinism - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Postprandial Period | Adult | Female | Hypoglycemia - blood | Hyperinsulinism - blood | Hyperinsulinism - metabolism | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Hyperinsulinism - prevention & control | Peptide Fragments - administration & dosage | Peptide Fragments - pharmacokinetics | Gastric Bypass - adverse effects | Hypoglycemia - metabolism | Pilot Projects | Hypoglycemia - etiology | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Infusions, Intravenous | Hypoglycemic Agents - adverse effects | Cohort Studies | Obesity | Career development | Glucose | Glucose tolerance tests | Surgery | Dextrose | Glucose tolerance | Intravenous administration | Gastric bypass | Dose-response effects | Injection | Hypoglycemia | Pharmacokinetics | Insulin
Journal Article
Journal Article
Journal Article
Diabetes Research and Clinical Practice, ISSN 0168-8227, 2012, Volume 97, Issue 1, pp. 27 - 42
Journal Article
Journal Article